B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Executive Director - Clinical Business Operations

Full-TimeUpdated on 10/15/2026
No salary listed
Expert
Bachelor's
Singapore
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • Strong planning and organizational skills, including the ability to lead a team effectively in a dynamic environment with competing priorities.
  • Strong executive communication skills and the ability to present data-driven insights to senior leadership.
  • A solution-driven, results-focused approach and willingness to take a hands-on approach to work.
  • Demonstrated ability to analyze complex financial data and translate insights into actionable guidance.
  • Experience working cross-functionally with Clinical Operations, Finance, Payments, and Legal stakeholders.
  • Advanced proficiency in Excel and data analytics tools.
  • Good knowledge of ICH-GCP and pharmaceutical-related regulations and laws.
  • A bachelor's degree or above in Life Sciences, Medical Science/Medical, Finance, Health Economics, or a related field.
  • 20+ years of experience in Clinical Operations, study start-up, clinical site budgets, or clinical site contracts within a pharmaceutical sponsor or CRO environment.
Responsibilities
  • Drive operational excellence, financial stewardship, compliance, scalability, and digital transformation initiatives across the Clinical Business Operations team.
  • Oversee investigator budgets, site contracts, site payments, and the budget data hub team to support accurate budget forecasting, efficient site contract execution, timely and accurate site payments, and accurate budget data entry in databases.
  • Lead Clinical Business Operations workforce planning, talent acquisition, succession planning, capability development, performance management, and team development.
  • Align regional execution strategies with global governance frameworks, including accountability models, decision-making processes, and issue escalation mechanisms across cross-functional and cross-country stakeholders.
  • Establish and lead recurring governance cadences, including quarterly business reviews, escalation forums, and executive reporting, to proactively manage and communicate risks, trends, and operational performance.
  • Own and monitor key operational and financial performance indicators across investigator budgeting, site contracting, payments, and budget data governance, including site contract cycle time and execution timeliness, budget forecast accuracy and forecast-versus-actual variance, and site payment timeliness and reconciliation accuracy.
  • Provide strategic oversight of investigator fee budget planning to support accurate financial forecasting.
  • Direct the development, review, negotiation, and timely execution of site budgets and clinical trial agreements in alignment with fair market value principles, study requirements, company standards, and study start-up timelines.
  • Supervise the end-to-end site payment and payment reconciliation processes to ensure financial obligations are processed accurately and in accordance with contractual terms and payment schedules.
  • Oversee the collection, validation, and maintenance of budget-related information in designated databases and systems to support data integrity and accuracy.
  • Ensure budget, contract, payment, and supporting operational documentation remains audit-ready and compliant with applicable regulatory, financial, and internal governance standards.
  • Maintain oversight of Sunshine reporting obligations and global transparency requirements, ensuring processes, controls, and stakeholder alignment are implemented across regions.
  • Provide strategic oversight of outsourced vendors and external business partners, including performance monitoring, service quality oversight, issue escalation, and governance.
  • Partner with Corporate Finance on financial governance, including oversight of accruals, forecast-versus-actual, and reconciliation processes.
  • Oversee operational finances and team resources to ensure activities remain within approved budgets and resource allocations.
  • Provide leadership, guidance, and performance management to team members, fostering accountability, collaboration, and continuous improvement.
  • Support implementation of automation tools and digital solutions to improve productivity.
Desired Qualifications
  • Experience with budget systems and contract lifecycle management platforms.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.